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LETTERS TO THE EDITOR 
We are pleased to receive Letters to the Editor on appropriate subjects. These letters should be submitted 
in typewritten form , double-spaced, and are not to exceed 2112 pages. When appropriate, we will solicit com-
ments from the original authors. All Letters to the Editor a re subject to editing a nd possible abridgment. 
X-RAY THERAPY FOR RADIATION 
To the Editor: 
As Chairman of the Committee on Ionizing Radiation and Medical 
Devices of the American Academy of Dermatology, I consider it my 
duty to write to you concerning the portion of the report that appeared 
in the J ournal of Investigative Dermatology , 73(5) (Part II): 482, 1979. 
It states: 
"Radiation. In the past radiotherapy was a frequently used treatment 
by dermatologists for both benign and malignant skin disease. At best 
the treatments produce palliation and at worst are hazardous. Conse-
quently, this type of physical treatment is on the 'way out', and there 
seems little likelihood of its return to favor." 
X-ray therapy for malignant conditions such as basal-cell carcinoma 
and squamous-cell carcinoma is still, today, an excellent method for the 
treatment of certain cancers of the skin. The cure rate is high and 
morbidity is low. In some, it is clearly the treatment of choice. Also, x-
ray therapy is probably the most frequently used modality in treating 
mycosis fungoides and Kaposi's sarcoma. 
I know of no better treatment of pseudolymphoma than x-ray 
therapy; in keratoacanthoma it is frequently used successfully when all 
other known methods have failed. 
In the light of the above how can the statement "At best the 
treatments produce palliation .... . " be justified? 
When properly used, modern x-ray therapy is safe. Therefore, the 
statement that x-ray treatments "at worst are hazardous" needs defin-
ing. 
I am sure that Drs. Odland and Van Scott meant to convey the 
meaning as I have suggested. I feel that there is no real basic difference 
among us. 
Arthur H. Gladstein, M.D. 
Professor of Clinical Dermatology 
Chairman, Committee on Ionizing Radiation 
and Medical Devices 
NYU School of Medicine 
TYROSINE AMINOTRANSFERASE ACTIVITY IN SKIN 
To the Editor: 
Pomerantz and Li [1] demonstrated a tyrosine aminotransferase 
activity (TAT) in mouse skin. In view of the interest of our laboratory 
in tyrosine metabolism and skin disease [2,3], we were stimulated by 
Pomerantz' results to investigate TAT (E.C.2.6.1.5) in human and rat 
s kin. 
Using the Diamondstone assay procedure for TAT [4], rat and 
human whole skin samples, and rat, mink and human liver samples 
were extracted for TAT [as described by us for liver [2]]. Protein was 
measured by the technique of Lowry et al [5). In addition to TAT 
assays all liver TAT preparations and a rat skin preparat ion were 
preincubated in the presence of 25 J.il rabbit anti-rat TAT (protein 
concentration 140 1-1gms/ ml; a gift of Dr. F. Kenney at Oak Ridge 
National Laboratory) for 5 min at 37°C, then assayed as usual for TAT 
activity. Rat skin and mink liver TAT were also assayed without 
additional ketoacid, and with oxaloacetate in place of alpha-ketoglutru·-
ate. 
Specimens of 12 mink livers, 7 rat livers, and 2 human livers were 
extracted and assayed for TAT activity; these were also assayed after 
preincubation with 5 1-1g of anti-rat liver TAT. Mink liver had an 
average rate of 11.89 (±3.96 SD) 1-1moles substmte/mg protein/ min with 
a maximum anti-TAT inhibition of about 60%; rat liver had an average 
rate of 2.6 (±3.57 SD) !-!IDOles substrate/mg. protein/ min. with 60% 
inhibition by anti-TAT; human liver had a rate of 13.47 1-1moles sub-
strate/ mg. protein/ min. with 33% inhibition by anti-TAT. Nonimmune 
rabbit serum had no effect on these liver preparations, and mink liver 
TAT preparations were unable to transaminate tyrosine when alpha-
ketoglutarate was replaced with oxaloacetate. 
Eight rat skin samples were extracted and assayed with an average 
rate of 2.32 (±0.85 SD) 1-1moles substrate/mg. protein/ min. When 
assayed without added alpha-ketoglutarate, activity was 48% of control 
levels, suggesting that some ketoacids were in the supernatant. More 
significantly, with oxaloacetate as cosubstrate, activity was 73% of that 
with alpha-ketoglu tarate. Since anti-rat TAT inhibited both human 
and mink liver TAT, it seemed logical to expect it to have some effect 
on TAT from a different organ in the same species. However, we found 
no inhibition of rat skin TAT with anti-rat liver TAT. 
Seven specimens of human skin were similarly extracted and assayed 
for TAT activity, with an average rate of 3.34 (±1.92 SD) 1-1moles 
substrate/mg. protein/ min. When assayed with no added ketoacid, 
about 43% of the activity with alpha-ketoglutarate remained. 
Although Pomerantz and Li showed mouse skin to contain a pyri-
doxal-5'-phosphate dependent aminotransferase which formed p-hy-
droxyphenylpyruvate, they have not convincingly proven it to be TAT. 
Authentic TAT is very fastidious in its requirement for alpha-ketoglu-
tarate, compared to other aminotransferases which can also catalyze 
the same transamination. Our results after replacing alpha-ketoglutar-
ate with oxaloacetate indicate the presence of an enzyme abl~ to 
transaminate tyrosine with either ketoacid as cosubstrate; results with 
oxaloacetate are not mentioned by Pomerantz and Li [1]. We interpret 
the lack of inhibition of rat skin TAT by anti-rat liver TAT to suggest 
that there is no immunoreactive TAT in rat skin. Therefore, in view of 
the ability of oxaloacetate to substitu te for alpha-ketoglutarate , the 
presence of significant activity without added ketoacid, and the lack of 
inhibition with anti-TAT, we suggest that the TAT-like activity in rat 
skin is not identical to hepatic TAT (E.C.2.6.1.5). 
Similar studies on mouse skin would be needed to definitively estab-
lish the nature of the TAT-like activity in that species. 
Confusion about multiple forms of TAT, and the question of "true 
TAT vs. pseudoisozymes" [6) has permeated the liver TAT literature 
for more than ten years. We believe it is important to further crit ically 
evaluate the presence ofT AT in skin , and to benefit from the extensive 
experience of those who have studied liver aminotransferases. 
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Lowell A. Goldsmith, MD 
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Department of Medicine 
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REPLY 
Thorpe and Goldsmith show that the control tyrosine aminotrans-
ferase (TAT) activity of rat skin supernatant (2.32 mole/ mg protein/ 
min in the presence of a-ketoglutarate was not inhibited by anti-rat 
TAT. Anti-rat TAT did partially inhibit TAT activities in livers from 
rats, minks, and humans. They show that 48% of the control activity in 
rat skin was present in the absence of a-ketoglutarate, and that the 
activity with oxalacetate in place of a -ketoglu tarate was 73% of control. 
In view of these fmdings, they conclude that the TAT activity in rat 
skin is not the same as the TAT of rat liver. They probably wish to 
implicate mitochondr ial aspartic aminotransferases (AAT) , since the 
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pig heart ATTs utilize tyrosine, phenylalanine, and tryptophan [1] and 
the rat liver AA T will utilize either a-ketoglutarate or oxalacetate as 
cosubstrates with tyrosine [2]. Their strongest evidence is the antibody 
data, since added oxalacetate might be exerting its effect through an 
initial transamination with endogenous glutamate to yield a-ketoglu-
tarate. 
The question raised by Thorpe and Goldsmith is whether the con-
version of tyrosine to p-hydroxyphenylpyruvate which we observed in 
the supernatant fraction of mouse skin from newborns is the result of 
the action of cytoplasmic tyrosine aminotransferase, or that of mito-
chondrial aspartic aminotransferase. We did not have available anti-rat 
liver TAT, and thus cannot give a definitive answer. We did show that 
the TAT activity in newborn mouse skin was inhibited by 2 compounds 
(p-hydroxy-phenylacetic acid and 3,4-dihydroxyphenylacetic acid) 
which also inhibit cytoplasmic TAT of rat liver to the same extent. It 
appears that the mitochondrial TAT activity has not been studied with 
these inhibitors. Although we measured the activity in a high speed 
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supernatant, it is still possible that the mitochondrial enzyme was 
extracted into the supernatant. The question thus remains open as to 
whether the activity measured in mouse skin belongs to tyrosine 
aminotransferase or to another aminotransferase of broad specificity. 
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Correction 
In the February 1980 issue of the Journal (vol. 74), Figures 1 and 2 (page 75) in the article "Epidermal 
Cyclic AMP Is Not Decreased in Psoriasis Lesions" by Adachi et al should have appeared on page 82 
instead of on page 75. Figures 1 and 2 (page 82) in the article "Increased Granulocyte Adherence in 
Psoriasis and Psoriatic Arthritis" by Sedgwick, Bergstresser, and Hurd should have appeared on page 75 
instead of on page 82. 
The illustrations and their correct legends appear here. 
Increased Granulocyte Aherence in Psoriasis and Psoriatic Arthritis 
Julie B. Sedgwick, M.S., Paul R. Bergstresser, M.D., and Eric R. Hurd, M.D . 
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FIG 1. Percent PMN adherence for control and psoriasis groups. 
Horizontal bars represent the man for each group. n.s. = not statisti-
cally significant. 
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FIG 2. Percent PMN adherence for normal controls, psoriatic arthl'itis 
patients and psoriasis patients according to extent of disease. Horizon-
tal bars represent the mean for each group. 
